Introduction
Intra-abdominal infections (IAIs) represent a diverse group of diseases that are encountered commonly in the care of critically ill patients. By definition, complicated IAIs extend beyond the source organ and into the peritoneal cavity through a perforated viscus, with subsequent induction of the systemic inflammatory response cascade. Whereas community-acquired IAI (CA-IAI) is characterized predominantly by enteric Gram-negative bacilli (GNB) and anaerobes that are susceptible to narrow-spectrum agents, healthcareacquired IAI (HA-IAI) (e.g., anastomotic dehiscence, postoperative organ-space surgical site infection) frequently involves at least one multidrug resistant (MDR) pathogen ( Fig. 1) , necessitating broad-spectrum therapy guided by both culture results and local antibiograms.
Although the fundamental treatment principles of source control, antimicrobial therapy, and restoration of a functional gastrointestinal tract (if possible) are applicable to the critically ill patient with an IAI, each of these issues becomes inherently more complex in this population. Furthermore, these objectives must be met with respect to, and in conjunction with, support of organ dysfunction and mitigation of deranged immune and coagulation responses.
Source control
Source control is defined as any and all physical means necessary to eradicate a focus or infection, as well as modify factors that maintain infection, such as leaking intestinal contents. Inadequate source control at the time of the initial operation has been associated consistently with increased mortality in patients with IAIs [1, 2] .
In cases of IAI complicated by septic shock, a single operation may not be sufficient to achieve source control, thus necessitating re-exploration. Three methods of local mechanical management following initial laparotomy for source control are currently debated: open-abdomen (also known as laparostomy); planned re-laparotomy; and on-demand re-laparotomy (ODR). Open-abdomen management involves temporary coverage of the abdominal contents with polyglactin mesh, towels, abdominal 'zipper', or vacuum-assisted closure [3] [4] [5] . In certain instances, this technique is mandated either to avoid abdominal compartment syndrome or because of physical inability to re-approximate the abdominal fascia regardless of intra-abdominal pressure. Open-abdomen management, however, may also be considered for cases in which source control is unclear or known to be inadequate [6] . Purported benefits of leaving the abdomen open to manage IAI include reduction in intra-abdominal pressure, more complete drainage of infection, early detection of additional anastomotic leaks or new abscesses, facilitation of reoperation (including serial laparotomies at the intensive care unit bedside), and minimization of additional abdominal wall trauma. These benefits may, however, be negated by the increased morbidity caused by fluid and protein loss, fistula formation, and ventral abdominal wall herniation [7, 8] .
Planned re-laparotomy involves the a priori decision to re-explore the abdomen regardless of clinical circumstance. By contrast, ODR is performed only in the case of subsequent re-infection, usually indicated by either clinical deterioration or failure to improve despite both presumed adequate source control and appropriate antimicrobial therapy. Planned re-laparotomy is indicated if adequate source control is clearly not obtained at the time of the initial operation. In all cases, the benefits of more effective source control must be weighed against the potential morbidity of bleeding, damage to edematous viscera or the abdominal wall [9] , and stimulation of additional inflammation [10] .
These three techniques (ODR, planned re-laparotomy, and open abdomen) have not been compared in a randomized fashion, and the observational descriptive literature is limited by subjective management decisions made by the surgeon at the time of the initial laparotomy. These decisions, in turn, depend on multiple clinical factors that determine patient outcome independent of management strategy, most notably the severity of illness. Methodological limitations notwithstanding, observational comparisons of the open abdomen and re-laparotomy (either planned re-laparotomy or ODR) techniques have not demonstrated a significant advantage to either [7, 11] . Furthermore, several studies, using a matched case-control design, have failed to show a benefit to the planned re-laparotomy as compared with the ODR approach after adjusting for severity of illness [12] [13] [14] [15] [16] . These findings were confirmed in a recent metaanalysis that, despite significant heterogeneity among studies, did not report a survival advantage to the planned re-laparotomy as compared with the ODR approach (pooled OR 0.70, 95% CI 0.27-1.80, P ¼ 0.50) ( Fig. 2 ) [17] . Multiinstitutional randomized controlled trials (RCTs), which theoretically eliminate confounding due to underlying clinical status or variations in patient management, are needed before any meaningful recommendations can be made.
Following removal of infected tissue, attention should shift to the restoration of anatomy and functionality of the gastrointestinal tract. Staging of procedures intended to restore intestinal continuity continues to be a matter of debate, particularly with respect to IAI caused by colonic perforations. In particular, there has been trepidation regarding performance of a primary colonic anastomosis Results from a study in which peritoneal isolates from 67 patients with postoperative peritonitis were compared with those of 68 patients with community-acquired peritonitis [64] . As a consequence of prior antimicrobial use, the flora of the peritoneum are altered. Whereas pathogens such as E. coli and streptococci are more commonly isolated in cases of community-acquired intra-abdominal infection (CA-IAI), enterococci and S. aureus are more prevalent in healthcare-acquired intra-abdominal infection (HA-IAI). Adapted with permission [64] . in the setting of acute inflammation, owing to the perceived increased risk of anastomotic failure, leakage, and HA-IAI. The past two decades have witnessed a shift from the traditional three-stage procedure (abscess drainage and proximal colostomy alone, then resection and anastomosis, followed by colostomy closure, in three separate operations) to the two-stage Hartmann procedure (primary resection with oversewing of the distal rectum and a proximal end-colostomy, followed by colostomy takedown and re-anastomosis on a second operation), with a decrease of associated mortality [18] . Most recently, several reports have touted the safety of a one-stage procedure for colonic perforation with associated peritonitis, involving abscess drainage, resection, and primary anastomosis [19] [20] [21] . Moreover, several authors have reported favorable results when colonic anastomotic leaks are managed with proximal diversion and surgical drainage only, in lieu of anastomotic resection [22] [23] [24] .
These nonrandomized trials, however, involved critically ill patients infrequently, and the extent of surgery should be dictated primarily by the degree of physiologic derangement, given the strong documented relationship between severity of illness and treatment failure.
Furthermore, disruption of a colonic anastomosis should not be equated with anastomotic disruption at other sites along the gastrointestinal tract. One exception of particular importance involves anastomotic leak following bariatric surgery, for which timely re-operation with revision is essential [25] . Finally, in the presence of hemodynamic instability, re-establishment of intestinal continuity of any kind may be contraindicated, necessitating re-laparotomy within the next 24-48 h.
Antibiotic therapy
An increasing prevalence of MDR pathogens isolated from cases of IAI underscores the urgent need for both the curtailment of unnecessary antibiotic use and the development of novel antimicrobial agents [26] [27] [28] .
In-vitro susceptibility of GNB isolated from IAIs are catalogued annually by the Study for Monitoring Antimicrobial Resistance Trends (SMART), which is an international surveillance program to monitor resistance patterns globally [29 ] . Andrus et al. 25 Penninckx et al. 31 Wittmann et al. 32 Hau et al. 27 Grunau et al. 25 Koperna and Schulz 28 Koperna and Schulz 29
of 980 Total
Individual and pooled odds ratios (planned versus on-demand re-laparotomy) for the eight studies included. Pooling was according to the randomeffects model. Squares and bars indicate study size and confidence interval, respectively. Elongated diamond represents the confidence interval of 0.27-1. 80 . Test for heterogeneity of the eight studies: the prevalence of MDR organisms such as Pseudomonas aeruginosa and Acinetobacter baumannii remained unchanged, antimicrobial resistance is increasing on an international scale, particularly to fluoroquinolones and b-lactam agents. Furthermore, MDR GNB have now been isolated from cases of CA-IAI in parts of South America and Asia.
Inadequate empiric antimicrobial therapy is an important contributor to this problem, as such therapy only increases the probability that both initial and subsequent antibiotic regimens will fail. The scope of the crisis is daunting; in a recent study of 425 patients with CA-IAIs from 20 clinics across Germany, approximately 25% (n ¼ 81/313) of all pathogens were resistant to one or more commonly-used antimicrobial agents, including 22% of E. coli (n ¼ 32/147), 23% of Klebsiella spp. (n ¼ 5/22), and 46% of Enterobacter spp. (n ¼ 6/13) [30] .
Data regarding antibiotic regimens for critically ill patients with IAIs are scant. Consequently, the intensivist is faced with the unsettling task of extrapolating results from extant clinical efficacy trials, which continue to enroll primarily low-risk subjects with CA-IAIs, the majority of which are due to appendicitis [31] [32] [33] . In these trials, mortality is a rare event, and clinical cure rates approach 100%. Trials sufficiently powered to conduct subgroup analyses of critically ill patients are lacking and clearly warranted [34] .
Such limitations not withstanding, evidence-based guidelines have been formulated by both the Surgical Infection Society (SIS) [35] and the Infectious Diseases Society of America (IDSA) [36] for selection of antimicrobial therapy for high-risk patients with IAIs. 'High-risk' patients with IAIs are generally regarded as those with one or more of the following parameters that have been associated consistently with increased mortality of patients with IAI: shock; increasing age; increasing Acute Physiology and Chronic Health Evaluation (APACHE) II score; isolation of enterococci; impaired consciousness; inadequate empiric antibiotics; poor nutritional status; cardiovascular disease; inability to obtain source control; immunosuppression; hypoalbuminemia; thrombocytopenia; diffuse versus localized peritonitis; symptoms more than 24 h before definitive intervention; subsequent nosocomial infection; protein C concentration below 66% of normal. Furthermore, all patients with risk factors for IAI caused by MDR pathogens are considered high risk. These risk factors include hospitalization over 48 h; immunosuppression; postoperative infection; recent antibiotic therapy; and residence in skilled nursing care or long-term care facility. Use of the threshold of hospitalization over 48 h has been arbitrary in large part. According to one recent study of patients with secondary peritonitis, use of a 5-day threshold was most accurate for predicting isolation of a multidrug-resistant pathogen, with a specificity of 58% and a sensitivity of 93% [37] .
According to the SIS guidelines, treatment options for high-risk patients include extended-range b-lactam/ b-lactamase agents such as piperacillin/tazobactam, carbapenems such as imipenem-cilastatin or meropenem, or a third or fourth-generation cephalosporin plus metronidazole. By contrast, the IDSA guidelines do not outline specific regimens for the treatment of high-risk patients, noting only that antibiotic therapy for such patients frequently requires the use of multidrug regimens. In all cases of IAI in the critically ill patient, regimens must be individualized according to local resistance patterns, and modified (as needed) based on antimicrobial susceptibility data obtained from cultured specimens. Pharmacokinetic and pharmacodynamic principles are also important with regard to antibiotic dosing for renal and hepatic dysfunction.
Shortage or unavailability of several recommended agents, including cefoxitin, ticarcillin-clavulanic acid, ceftizoxime, and cefotetan, has limited further the antimicrobial armamentarium for the treatment of IAIs. Fluoroquinolones should be used judiciously based on resistance emerging internationally [29 ] . The use of aminoglycosides for the treatment of IAIs has recently come under scrutiny. Both the need to monitor serum drug concentrations and potential ototoxicity and nephrotoxicity represent disincentives to selecting these agents as first-line therapy. Bailey et al. [38] pooled results from 47 randomized controlled trials conducted from 1981 to 2000, which compared aminogylcosides with other agents for the treatment of IAIs. Despite significant heterogeneity among studies, the pooled odds ratio for clinical efficacy favored the comparator regimen (OR 1.19, 95% CI 1.01-1.41, P ¼ 0.04). Unfortunately, adverse drug events were reported inconsistently among studies.
A second meta-analysis pooled results from 19 studies that compared an aminoglycoside plus an anti-anaerobe with a variety of comparator regimens [39] . Although there was no difference in either all-cause mortality (OR 2.03, 95% CI 0.88-4.71) or mortality due to infection (OR 1.51, 95% CI 0.78-5.65) when comparing the aminoglycoside with the comparator group, there was a statistically significant decrease in both clinical success rates (OR 0.57, 95% CI 0.41-0.78, P ¼ 0.0005) and microbiologic success rates (OR 0.49, 95% CI 0.31-0.76, P ¼ 0.001), raising the possibility of inadequate dosing. Again, adverse drug events were reported infrequently.
Although the results of these meta-analyses appear to discourage the use of aminoglycosides for the treatment of IAIs, several caveats must be considered. As mentioned previously, inadequate dosing may have underestimated efficacy. No trial of antimicrobial therapy of IAI to date has employed once-daily dosing of aminoglycosides. Furthermore, results may have been biased inherently due to frequent comparison of a novel agent with an aminoglycoside. Finally, caution must again be exercised when extrapolating these studies of low-risk patients to therapy of critically ill patients.
The use of b-lactam-aminoglycoside combination therapy as compared with b-lactam monotherapy for the treatment of critically ill patients with sepsis appears to offer no additional benefit, at the cost of nephrotoxicity. Paul et al.
[40 ] reviewed 64 trials of patients with sepsis, including 11 trials that were limited to patients with IAIs. Neither all-cause fatality (RR 1.01, 95% CI 0.75-1. 35) nor clinical failure (RR 1.11, 95% CI 0.95-1.29) was affected by the addition of an aminoglycoside as compared with monotherapy. The risk of nephrotoxicity was significantly decreased in the monotherapy group (RR 0.30, 95% CI 0.23-0.39).
Newer agents that have demonstrated noninferiority when compared with standard broad-spectrum regimens for the treatment of patients with IAIs include tigecycline [41, 42] , ertapenem [43] , and moxifloxacin [44] . Among these drugs, ertapenem is appealing because of oncedaily dosing and possible decreased induction of MDR GNB [45] . Whether these drugs should be used empirically for HA-IAI is unknown, however, particularly because the antipseudomonal activities of tigecycline and ertapenem, in particular, are unreliable.
Although a recent Cochrane Collaboration review of antimicrobial therapy for IAIs was unable to demonstrate clinical superiority of any one regimen [39] , recent work using Monte Carlo simulations to model the probability of adequate coverage of pathogens isolated commonly from patients with IAIs revealed substantial variability among regimens tested [46 ] . In this simulation, published antimicrobial pharmacodynamic data were modeled against minimum inhibitory concentration (MIC) information for a variety of bacteria obtained from the 2004 Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) database. Results for each agent tested (Table 1) are expressed as the cumulative fraction of response (CFR), which is defined as the expected population probability of target attainment for a specific drug and dose against a specific population of pathogens. Target attainment, in turn, is based on the percentage of the dosing interval during which free drug concentration remains above the MIC ( fT> MIC ) for compounds whose killing is time-dependent (e.g., b-lactams), or the ratio of the area under the concentration-time curve to the MIC for compounds whose killing activity is concentrationdependent (e.g., fluoroquinolones). As shown in Table 1, whereas the carbepenems, piperacillin/tazobactam, ceftazidine, and cefepime all returned CFRs over 90%, ceftriaxone, ciprofloxacin, and levofloxacin each returned a CFR under 82%. Despite the limitations inherent to simulation, pharmacodynamic modeling offers a useful adjunct in cases for which extant clinical efficacy data are ambivalent.
Continuous infusion of piperacillin/tazobactam has been investigated recently as an alternative to traditional intermittent dosing for the treatment of complicated IAIs. Continuous infusion offers the theoretical advantage of an increased fT> MIC [47, 48] . Lau et al. [49] randomized 262 patients with complicated IAIs to receive piperacillin-tazobactam by either intermittent (3 g/0.375 g over 30 min every 6 h) or continuous (12 g/1.5 g over 24 h) infusion. The mean APACHE II score was 8 points for both groups. Rates of clinical success, microbiologic success, and adverse events were similar between groups. A subsequent pharmacoeconomic analysis of this trial revealed no difference in overall costs of treatment when comparing the groups, although significantly lower labor and supply costs were observed in the continuous infusion group [50] . Although this study suggested noninferiority at a minimum, it is likely that most pathogens isolated were highly susceptible to piperacillin/tazobactam regardless of infusion modality. It is thus possible that the relative benefits of a continuous infusion are enhanced in the setting of critical illness, in which case resistance is more common. Pending data from a critically ill patient population specifically, formal recommendations cannot be made.
The optimal duration of antimicrobial therapy for critically ill patients with IAIs remains unknown [51] . Ideally, CFR, cumulative fraction of response; CI, confidence interval. a 90% predicts optimal antimicrobial activity against targeted pathogens. Adapted with permission [46 ] .
antimicrobial therapy should be discontinued as soon as possible in order to minimize both adverse drug events as well as the emergence of MDR pathogens. Current recommendations [35, 36] advise continued therapy until clinical signs of infection have resolved, including fever and abdominal pain, normalization of the white blood cell count, and restoration of gastrointestinal function. Provided these criteria are met, the likelihood of re-infection after discontinuation of antibiotic therapy of CA-IAI is exceedingly small [52, 53] . Typically, this will involve 5-7 days of therapy. Unfortunately, it is unlikely that common surgical practice reflects these guidelines accurately; one recent report found the mean institutional duration of antimicrobial therapy for patients with IAI to be 14.5 days [54] .
Shorter courses of antimicrobial therapy have been proposed, with the rationale being that resolution of clinical and radiographic parameters typically lags the eradication of infection [55] . An abbreviated treatment course did not result in an increase in treatment failures among a population of patients with ventilator-associated pneumonia, provided that the infection was not caused by nonfermenting GNB [56] . Attenuated antimicrobial therapy for complicated appendicitis has also been achieved without increased morbidity [57, 58] . Hedrick and Sawyer [54] studied 929 patients with IAI (the majority of which were HA-IAI) categorized based on the duration of antibiotic therapy. After controlling for age, APACHE II score, need for blood transfusion, ventilator dependence, and sex, shorter courses of antibiotics were associated with lower recurrence rates. Patients were also compared based on the criteria employed regarding discontinuation of antimicrobial therapy. Compared with patients for whom physiologic criteria were used (i.e., resolution of fever and leukocytosis), patients for whom a fixed duration of antimicrobial therapy was prespecified had fewer antibiotic days with similar outcomes. Although such results are encouraging in light of the aforementioned resistance pandemic, future RCTs that study duration of therapy as a primary endpoint are needed prior to amending current guidelines. At a minimum, the intensivist should strive to discontinue antimicrobial therapy within the specified 5-7-day timeframe provided that clinical deterioration has not occurred.
Although enterococci are isolated in as many as 25% of IAIs [59, 60] , they are almost always found in the setting of polymicrobial infection. Isolation of enterococci from IAIs is associated with HA-IAI as opposed to CA-IAI, increasing age, more severe disease, co-isolation of MDR pathogens such as P. aeruginosa, and increased mortality [61, 62] . The therapeutic implications, however, of the association between enterococci and adverse outcomes in patients with IAIs remain unclear [63] . Several RCTs, albeit of noncritically ill patients for the most part, have shown that treatment of such infections with antibiotic regimens that lack enterococcal activity does not result in treatment failure due to enterococcal infection [59, [64] [65] [66] [67] [68] [69] [70] [71] [72] . Consequently, routine coverage of enterococci in cases of CA-IAI is not recommended [35, 36, 63] . Conversely, most authorities maintain that empiric coverage of enterococci should be considered in certain clinical circumstances: HA-IAI; immunocompromise; presence of prosthetic heart valve; prior cephalosporin or carbapenem therapy; severe sepsis or septic shock; tertiary peritonitis.
Systemic antifungal therapy for treatment of Candida spp. isolated from critically ill patients with IAIs is also controversial, as highlighted by a recent review article [73] . Although Candida isolated from peritoneal fluid in cases of IAI has been associated with increased mortality [74, 75] , the issue of attributable mortality remains unresolved [76] . In general, treatment of Candida isolated from cases of CA-IAI in the immunocompetent host does not impact upon survival [75] . Available data, however, suggest that Candida isolated from critically ill patients who are immunocompromised, as well as Candida isolated from cases of either HA-IAI or IAI associated with severe sepsis, warrant initiation of empiric antifungal therapy, typically with intravenous fluconazole [73, 77, 78] . Furthermore, isolation of fungi from two or more normally sterile sites (e.g., peritoneal cavity and lower respiratory tract) of critically ill patients should prompt consideration of antifungal therapy.
Recombinant human activated protein C
Drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)] gained approval worldwide for the treatment of severe sepsis associated with a high risk of death in 2001 following a pivotal RCT that demonstrated a relative risk reduction for mortality of 19% for patients treated with rhAPC as compared with placebo [79] . Initial concern was raised for the use of APC specifically in surgical patients because of an attenuated absolute risk reduction for mortality compared with the overall sample (3.2% versus 6.0%, respectively), as well as an increased risk of bleeding. In response to this criticism, a surgical evaluation committee adjudicated the results of the original trial for surgical patients (n ¼ 474/1690, 28.0%), and specifically for those surgical patients with severe sepsis of abdominal origin (n ¼ 295/474, 63.0%) [2] . Among those patients undergoing abdominal procedures, the absolute risk reduction was 9.1%, and the relative risk of 28-day mortality was 0.70 (95% CI 0.48-1.03). In a subgroup of these patients with an APACHE II score 25 points or higher, the absolute risk reduction was 18.2%. Furthermore, the rates of serious bleeding events among patients who received rhAPC did not differ between the surgical and nonsurgical cohorts ( Fig. 3) .
A more recent analysis of the INDEPTH database, which currently contains five clinical trials of the efficacy of rhAPC, demonstrated a significant risk reduction for mortality (adjusted OR 0.66, 95% CI 0.45-0.97) for rhAPC as compared with placebo among high-risk (APACHE II score 25 points) surgical patients, over one-half of whom had IAIs [80 ] . Finally, a recent analysis using a matched cohort design of patients with septic shock of abdominal origin from our institution revealed a more than five-fold increase in the likelihood of mortality in controls as compared with patients who received rhAPC [81] .
Tertiary peritonitis
Tertiary peritonitis is defined as peritonitis that persists after more than one failed source control procedure [82] . Management of tertiary peritonitis presents a particular challenge due to poorly localized IAI, prolonged systemic inflammation, organ dysfunction, an increased likelihood of infection with MDR organisms, and the frequent need for re-laparotomy in hemodynamically tenuous patients [82] . Whether tertiary peritonitis represents invasive infection or colonization in the setting of complete failure of abdominal host defenses is controversial. Unfortunately, parameters associated traditionally with poor outcomes in critically ill patients, such as advanced age, increasing APACHE II score, and immunosuppression, appear unable to predict the development of tertiary peritonitis [82, 83] . Due to the poor prognosis associated with tertiary peritonitis, it is generally recommended that both enterococci and fungi, if isolated, should be treated. In addition to appropriate antimicrobial therapy, frequent re-evaluation of source control and support of organ dysfunction comprise the mainstays of treatment. Fortunately, the incidence of tertiary peritonitis is decreasing [83] .
Outcomes
A number of parameters are known to affect outcomes in critically ill patients with IAIs and may be divided broadly into patient demographics (e.g., acuity, comorbidity), preoperative factors (e.g., rapidity of diagnosis), operative factors (e.g., attainment of source control), and postoperative factors (e.g., development of organ failure). Merlino et al. [84] reviewed 168 patients over a 6-year period in order to determine the impact of a subsequent nosocomial infection on outcomes in patients with IAI. Age 50 years or above, APACHE II of 10 or above, and the development of a nosocomial infection were associated independently with mortality. Increasing age, acuity, and comorbidity all predicted independently the development of a nosocomial infection.
The ultimate goal of the aforementioned improvement in prognostic, diagnostic, and therapeutic modalities is to improve the substantial mortality of critically ill patients with IAIs. We studied longitudinal outcomes for 465 critically ill surgical patients with IAIs over an 11-year period (1991-2002) [85] . Both the magnitude of organ dysfunction (r 2 ¼ 0.11) and mortality (r 2 ¼ 0.01) remained constant over the study period despite a significant increase in acuity over time (r 2 ¼ 0.71, P < 0.0001), resulting in a significant decrease in risk-adjusted mortality (<0.01). Mortality for 2002, however, the most recent year included, exceeded 20%, underscoring the need for continued improvement. 
Conclusion
Although much research into the management of critically ill patients with IAIs is needed, certain salient themes have emerged from extant literature. Most notably, appropriate empiric antimicrobial therapy, as well as timely discontinuation of such therapy, is paramount to curtailing the continued problem of multidrug resistance. Broad-spectrum therapy, when indicated, should provide adequate coverage against likely MDR pathogens, but should then be re-evaluated frequently and modified based on culture results, striving to achieve the minimum possible duration of therapy. Importantly, persistent or additional antimicrobial therapy should never serve as a substitute for adequate source control. Finally, rhAPC has emerged as an evidence-based therapy for patients with severe sepsis of abdominal origin associated with a high risk of death. It is the authors' hope that the research agenda in the near future will devote attention in the form of prospective trials to the often-neglected population of critically ill patients who suffer from IAIs.
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